Gangliosides--a new therapeutic agent against stroke and Alzheimer's disease.
Gangliosides are glycosphingolipids localized to the outer leaflet of the plasma membrane of vertebrate cells. The highest ganglioside concentration of any organ is found in the mammalian brain, where the gangliosides are enriched in the neuronal membrane, particularly in the synapses. There are four major brain gangliosides with the same neutral tetrasaccharide core to which one to three sialic acids are linked--the simplest being the GM1-ganglioside. These gangliosides have been shown to have neuritogenic and neuronotrophic activity and to facilitate repair of neuronal tissue after mechanical, biochemical or toxic injuries. Mixtures of native bovine brain gangliosides were adopted for pharmacological use in the treatment of peripheral nerve damage, and GM1-ganglioside has been applied for the treatment of CNS injuries and diseases. Beneficial effects of GM1 have been documented in the treatment of stroke and spinal cord injuries, particularly when the treatment has been initiated within a few hours of the acute event. Continuous intraventricular infusion of GM1 has recently been shown to have a significant beneficial effect in Alzheimer disease of early onset (AD Type I).
Svennerholm
L
L
Department of Clinical Neuroscience, University of Göteborg, Mölndal Hospital, Sweden.
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D002240:Carbohydrate Sequence; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000503:physiopathology; D005677:G(M1) Ganglioside / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008969:Molecular Sequence Data; D013119:Spinal Cord Injuries / Q000188:drug therapy
D005677:G(M1) Ganglioside